Newsfeeds - Spark Newswire

5 minute read

77 Biggest Movers From Yesterday

Today, 5:39 AM

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners.

ACOR

3 minute read

40 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 5:39 AM

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 360.8% to $9.86 after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners.

AMR

1 minute read

Recap: Myriad Genetics Q1 Earnings

By Benzinga Insights

Today, 5:39 AM

Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM. Here's what investors need to know about the announcement.

MYGN

30 minute read

Earnings Scheduled For May 5, 2022

By Benzinga Insights

Today, 5:39 AM

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

48 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 5:39 AM

During Thursday, 849 stocks hit new 52-week lows.

AADI

1 minute read

FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis

By Vandana Singh

Today, 5:39 AM

The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a…

2 minute read

Legal
News

Myriad Genetics 8-K Shows Co. Settled Qui Tam Suit Filed By STF LLC Against Co.’s Crescendo Bio Subsidiary, Co. To Pay $45.25M

By Benzinga Newsdesk

Today, 5:39 AM

On April 1, 2022, Myriad Genetics, Inc. (the “Company”) settled the qui tam lawsuit that was filed by STF, LLC (“Relator”) against Crescendo Bioscience, LLC (formerly known as Crescendo

MYGN

3 minute read

Myriad Genetics Announces Launch Of Precise Oncology Solutions

By Bill Haddad

Today, 5:39 AM

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the launch of Precise™ Oncology Solutions, a comprehensive offering designed to help oncologists

MYGN